Differences in clinical pharmacology of the currently marketed phosphodiesterase (PDE)5 inhibitors sildenafil, vardenafil and tadalafil are largely determined by their pharmacokinetic (PK) properties and their PDE5 inhibitory activity profile. This review outlines the basic concepts of pharmacokinetics and pharmacokinetic pharmacodynamic (PK/PD) relationships and their relevance to dose selection and applied pharmacotherapy. It is followed by a detailed comparative discussion on the pharmacokinetics and exposure-response relationship of the currently available PDE5 inhibitors, including known drug-drug interactions and dosage adjustments in special populations. The review is aimed at providing a critical assessment of the pharmacokinetics of PDE5 inhibitors, which may assist clinicians in tailoring drug and/or treatment regimens to the unique needs of each individual patient with erectile dysfunction.
Introduction
Pharmacotherapy with the three Food and Drug Administration (FDA)-approved phosphodiesterase (PDE)5 inhibitors, sildenafil, vardenafil, and tadalafil, is currently the mainstay of treatment for erectile dysfunction (ED). These three PDE5 inhibitors share the same mechanism of action, but there are noted pharmacodynamic (PD) differences between the compounds regarding their selectivity and specificity for PDE inhibition with consequences predominantly for their safety profile, as well as biopharmaceutic and pharmacokinetic (PK) disparities that largely affect their efficacy profiles. As more PDE5 inhibitors become available, clinicians are increasingly being asked to differentiate among these alternative treatment options in their therapeutic recommendations, but have also the opportunity to individualize therapy with PDE5 inhibitors to meet the medical and lifestyle needs of the individual patient. Knowledge of the PK and PD properties of these compounds is imperative for understanding their clinical pharmacology and provides the basis for a rationale, scientifically based pharmacotherapy. Thus, the present article reviews basic principles in clinical pharmacology with focus on pharmacokinetics and exposure-response relationships and subsequently discusses the relevance of these concepts for the pharmacotherapy with currently available PDE5 inhibitors.
The role of clinical pharmacology in pharmacotherapy
The rational use of drugs and the design of effective dosage regimens are facilitated by the appreciation of the central paradigm of clinical pharmacology that there is a defined relationship between the administered dose of a drug, the resulting drug concentrations in various body fluids and tissues, and the intensity of pharmacologic effects caused by these concentrations. In clinical practice, this relationship between the concentration (exposure) and its beneficial and/or toxic effects (response), however, is not always simple, but may be obscured by intermediate processes that may lead to a temporal dissociation between the time courses of concentration and effects, or by imprecise outcome measures that are unable to delineate subtle difference in response within a relatively high level of measurement noise. 1 These dose-exposure-response relationships and thus the dose of a drug required to achieve a certain effect are determined by the drug's PK and PD properties. Pharmacokinetics describes the time course of the concentration of a drug in a body fluid, preferably plasma or blood that results from the administration of a certain dosage regimen. In simple words, pharmacokinetics is 'what the body does to the drug'. Pharmacodynamics describes the intensity of a drug effect in relation to its concentration in a body fluid, usually at the site of drug action. It can be simplified to 'what the drug does to the body'. 2 The plasma concentration-time profile resulting from drug administration is determined by PK parameters and the administered dosage regimen. Whereas the PK parameters are characteristic for the disposition or handling of a drug in a specific patient and can thus usually not be modulated during pharmacotherapy, the dosage regimen is the clinician's tool to affect drug concentrations for maximum therapeutic benefit. 3 Generally, a drug is introduced (administration) into the body at a location remote from the intended effect site. Following uptake into the systemic circulation (absorption), it is transported to and taken up into various organs and tissues including its target sites (distribution). Some drugs are chemically altered (metabolism) by the body before they perform their action (e.g. activation of so-called prodrugs); others are metabolized afterwards; and still others are not metabolized at all. Finally, the drug and its metabolites are removed from the body (excretion).
General PK principles
Absorption As the overwhelming majority of drugs are intended to be administered orally, the ability of a compound to achieve activity after the administration via the oral route, that is a good bioavailability, is imperative. Absorption in vivo is a complex phenomenon, involving several possible mechanisms, although passive diffusion has been identified as the predominant mechanism of gastrointestinal absorption for most commercial drugs. 4 The most relevant factors that regulate the passive diffusion of drugs across the gastrointestinal mucosa are their physicochemical properties, including lipophilicity, solubility, polarity and ionization status. Physiological characteristics such as gastric emptying time and pH conditions throughout the gastrointestinal tract (GIT) also affect oral absorption. The presence of food, other drugs and certain digestive disorders may further alter the rate and extent of absorption. For example, high-fiber food may bind drug substance and prevent it from being absorbed. On the contrary, bioavailability of poorly soluble, lipophilic drugs may be enhanced when taken with fatty meals. 3 Drug that is absorbed in the GIT is first transported via the portal vein to the capillary bed of the liver before it reaches the systemic circulation. Thus, the liver is the first major elimination organ which any drug encounters following oral administration. This phenomenon is referred to as first-pass metabolism. The hepatic extraction ratio is the fraction of a dose that is removed during the first passage of the liver and does not reach the systemic circulation. Apart from liver, orally administered drug may also be metabolized by enzymes expressed in the gut wall or may be degraded in the lumen of the GIT before it ever reaches the systemic circulation.
Distribution
Once drug has entered the vascular system, it becomes distributed throughout the various tissues and body fluids. However, most drugs do not distribute uniformly throughout the body. This heterogeneous distribution is based on tissuespecific differences in rate and extent of drug uptake, including blood flow, that is, the delivery of drug to the tissues, the ability for the drug to cross biomembranes, partitioning into the tissue, and drug binding to tissue elements including binding to proteins and other macromolecules. For example, hydrophilic drugs tend to stay within the blood and the interstitial fluid, whereas lipophilic drugs tend to concentrate in tissues with high fat content.
Many drugs interact with plasma or tissue proteins or with other endogenous macromolecules to form drug-macromolecule complexes generally referred to as protein binding of a drug. Protein binding is a major determinant for drug disposition and efficacy. Drug bound to protein is not pharmacologically active, is for most drugs not accessible for drug-metabolizing enzymes and excretion processes, and is not able to pass biomembranes. In contrast, free drug is relevant for the pharmacological effects as it can interact with its target structure, for example, a receptor or ion channel, can be metabolized and excreted, and may pass biomembranes by passive diffusion. Thus, only free drug concentrations are ultimately relevant to pharmacotherapy. 5 Pharmacokinetics and pharmacodynamics in PD-5 inhibitor therapy B Meibohm et al
Metabolism
Elimination of drugs occurs by metabolism and excretion. The basic purpose of metabolism in the body is to convert the drug via a chemical reaction to more water-soluble metabolites that can be more readily excreted into the urine or bile. 6 Drug metabolism by its nature is a multifactorial process and there are usually multiple pathways involved. These include asynthetic Phase I reactions (e.g. oxidation, reduction, hydroxylation, dealkylation) and Phase II conjugation reactions (e.g. glucuronidation, sulfation, methylation). Frequently, a drug simultaneously undergoes metabolism by several competing pathways, where the fraction of metabolite formation is determined by relative rates and affinities of each of the parallel pathways. Metabolites may undergo further sequential metabolism, for example, Phase I reactions are often followed by a Phase II reaction. 7 Metabolic conversion usually decreases or diminishes the pharmacologic activity of a drug, but depending on the structure-activity relationship for the drug target, metabolites may have similar or even higher activity than their parent compound.
The most important enzyme family, based on the proportion of drugs and endogenous compounds that are metabolized by it, is the cytochrome P-450 (CYP) system, which is involved in the oxidative metabolism of many drugs. CYP enzymes are most predominant in the liver but are also found in the intestine, the lungs, and other organs. 8 The CYP3A subfamily (CYP 3A4, 3A5, and 3A7) accounts for the majority of drugmetabolizing enzymes present in the human liver and intestine. CYP3A4 is the most abundantly expressed CYP in both human liver and small intestine. It accounts for approximately 30-40% of the total CYP content in both tissues and is responsible for the metabolism of about 50% of all drugs currently prescribed. 9 Other major CYP enzymes responsible for drug metabolism are CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1. 7 The activity of CYP isoenzymes as well as other drug-metabolizing enzyme systems is dependent on genetic factors, concomitant drug therapy (drugdrug interactions), and is also affected by age, nutrition, and other environmental factors. Knowledge of the substrates, inhibitors, and inducers of CYP isoenzymes assists in predicting clinically significant drug-drug interactions and allows explaining and predicting part of the frequently observed interindividual variability in pharmacokinetics and thus drug response.
Genetic variations affecting functional activity have been identified for several Phase I and Phase II drug-metabolizing enzymes. Functionally relevant polymorphisms with impaired activity have for example been described for CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A5. 10, 11 Excretion Excretion of drug or drug metabolites from the body can take place through numerous pathways (kidney, liver, lung, skin, etc.), but the most significant organ for excretion is the kidney. Excretion of unchanged drug or drug metabolites via the kidneys is the net result of three processes, glomerular filtration, active tubular secretion, and tubular reabsorption. Glomerular filtration as a passive process removes all molecules of low molecular weight (MW oB20 000) out of plasma, but is limited to the fraction of drug not bound to plasma proteins. Thus, changes in the extent of plasma protein binding may modulate the renal excretion of a drug. 3 Compounds that are metabolized in the liver are often excreted via the bile into the intestinal tract, especially if they have undergone significant conjugation. The rate and extent of biliary elimination depends on molecular weight, chemical structure, polarity, and the nature of metabolic process. 12 Conjugated drug or metabolite molecules excreted into the bile can either be excreted via the feces or can be reabsorbed from the lumen of the GIT into the circulation after deconjugation by the gastrointestinal microflora (enterohepatic recycling). 13 Key PK parameters: theory and rationale A typical plasma concentration time profile after oral drug administration is shown in Figure 1 . MEC and MTC are the 'minimum effective concentration' and 'maximum tolerated concentration', respectively. MEC represents the minimum concentration needed to produce the desired pharmacological effect assuming there is rapid equilibration of drug concentration between plasma and the target site, and the pharmacologic effects are directly and reversibly related to the target site concentration. MTC is an upper limit of concentration beyond which concentration-related adverse events are intolerable. The 'onset time' is the time required for the drug to reach MEC after administration. The 'duration of action' is the difference between the onset time and the time for the drug to decline back to MEC. C max , the maximum concentration achieved, is a function of the rate and extent of drug absorption, whereas t max , the time required to achieve C max , is indicative of rate of absorption. The area under the curve (AUC) is a function of the extent of absorption and represents the overall systemic exposure of the drug.
Biological variability in pharmacodynamics as well as its modification by physiological, pathophysiological, and environmental factors results in between-patient variability in MEC and MTC. Considering this variability allows defining a drugspecific therapeutic range. A therapeutic range is a range of drug concentrations within which the Pharmacokinetics and pharmacodynamics in PD-5 inhibitor therapy B Meibohm et al 255 probability of desired clinical response in the considered patient population is relatively high and the probability of unacceptable toxicity is relatively low. The therapeutic range approach combines between-patient PD variability for the therapeutic as well as toxic effects of a drug.
The utility of pharmacokinetics lies in deciding the optimum dosage regimen, that is, the best way to administer a given drug to achieve its therapeutic objective, for example, maintaining the concentration within the therapeutic range. The dosage regimen defines 'How Much?' and 'How Often?' a drug must be taken to achieve this objective. It is these two questions that form the basis for the discipline of pharmacokinetics. The four basic PK parameters determining a dosage regimen are discussed in the following section.
Bioavailability
Bioavailability is the rate and extent of systemic absorption. The extent of bioavailability (F) of a drug is defined as the fraction of the administered dose that is available to the systemic circulation. F ranges from 0 (0%; no drug absorption) to 1 (100%; complete drug absorption). Absolute bioavailability compares an extravascularly administered dose to an intravenous dose administration, which, by definition, has an F of 1. Relative bioavailability compares two formulations given via extravascular routes relative to each other. As the systemic exposure AUC is in most cases directly proportional to F, bioavailability can be determined by comparing the respective dose normalized AUCs of a drug after different modes of administration.
Bioavailability can be viewed as the result of a combination of processes that reduce the amount of extravascularly administered drug that reaches the systemic circulation:
where F a is the fraction absorbed across the intestinal wall, and F g and F h are the fractions of drug that escape presystemic gut wall metabolism and hepatic first-pass metabolism, respectively.
Clearance
Clearance is a measure of the efficiency of drug elimination. Organ clearances can be defined as the volume of blood or plasma that is completely cleared from drug per unit time by the organ. It can be expressed as the product of the organ blood flow and the extraction ratio of the organ, the fraction of drug removed from the bloodstream per passage through the organ. The total body clearance is the sum of all individual organ clearances that contribute to the elimination of a drug, for example, renal clearance, hepatic clearance, and others. The parameter clearance is of crucial importance for determining 'how much' of a drug should be given, as systemic exposure AUC is only determined by dose (D), bioavailability F, and clearance CL:
AUC ¼ FÂD CL As the absolute bioavailability of orally administered drugs is frequently not known, especially if no i.v. dosage form is available, the term 'oral clearance' (CL/F) as ratio of clearance and extent of bioavailability is frequently used instead of systemic 
Volume of distribution
The volume of distribution (V) is a hypothetical concept that helps in quantifying the distribution of the drug, and is more correctly referred to as apparent volume of distribution. It assumes that a drug distributes homogeneously throughout the body and can be seen as a proportionality factor that relates the amount of drug in the body to the concentration measured in plasma. As only the unbound drug can diffuse across membranes, it is implicit that the distribution to tissues is affected by plasma protein binding. It is also important to understand that for drugs with significant tissue binding, the apparent volume of distribution can far exceed total body water. Drugs, which are highly bound to plasma proteins (plasma protein binding btissue protein binding), are contained in plasma water and have smaller volume of distribution compared to drug with low binding to plasma proteins.
Half-life
Half-life (t 1/2 ) characterizes the monoexponential decline in drug concentration after drug input processes have been completed and is the time required for the plasma concentration to decrease by one-half. Half-life (t 1/2 ) is a secondary PK parameter that is defined by the independent primary parameters clearance and volume of distribution:
693ÂV CL Half-life provides important information about specific aspects of a drug's disposition, such as how long it will take to reach steady state once maintenance dosing is started and how long it will take for 'all' the drug to be eliminated from the body once dosing is stopped (usually considered five halflives). As half-life also determines the fluctuation between minimum and maximum concentrations during a multiple dose regimen, it is the major determinant of the dosing interval between two consecutive doses, that is, how often a dose should be given.
Exposure-response relationships
Integrated PK/PD modeling allows a quantitative description of the dose-exposure-response relationship by linking the concentration-time course resulting from a dosing regimen as assessed by pharmacokinetics to the intensity of observed response in relation to drug plasma concentrations as quantified by pharmacodynamics. The resulting PK/PD models allow a description of the complete time course of the intensity of desired and/or undesired effects resulting from a certain dosing regimen ( Figure 2) . 5, 14 PK relationships are linear for most drugs, that is, follow the principle of superposition. In contrast, Figure 2 General concept of pharmacokinetic/pharmacodynamic (PK/PD) modeling. PK/PD modeling combines a PK model component that describes the time course of drug in plasma and a PD model component that relates the plasma concentration to the drug effect in order to describe the time course of the effect intensity resulting from the administration of a certain dosage regimen (from Derendorf and Meibohm 5 ).
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E ¼ E max ÂC EC 50 þ C where E max is the maximum effect possible with the specific drug and EC 50 is the concentration that causes 50% of E max , the half-maximum effect. E max refers to the intrinsic activity of a drug, EC 50 to its potency. This model assumes that under PK steadystate conditions, the observed effect is related to the effect site concentration that is in equilibrium with the plasma concentration.
If the concentration effect-relationship is poorly described, exposure-response assessments can also be performed by directly relating dose to an integrated measure of response, for example an average or maximum effect level. While temporal aspects in the exposure-response relationship may be neglected by this approach, it might serve as an alternative if data for more complex PK/PD analyses are not available. The E max model can also be used in this situation, with concentrations substituted by doses and a potency parameter of ED 50 instead of EC 50 .
The PK and PD of PDE5 inhibitors
A comparison of the most relevant PK and PD parameters for sildenafil, vardenafil, and tadalafil is provided in Table 1 .
Absorption of PDE5 inhibitors
All three currently available PDE5 inhibitors are rapidly absorbed after oral administration with a similar onset time, and peak concentrations slightly earlier reached for vardenafil compared to sildenafil and tadalafil. Following oral administration, sildenafil is rapidly absorbed, reaching C max within 1 h (range: 0.5-2 h) in the fasted state. The onset time is usually 30 min to 2 h after administration, although onset times as early as 11 min post-dose have been reported. 16 Vardenafil is also rapidly absorbed, with an onset time leading to intercourse completion usually 30 min to 2 h post-dose, although it has been reported as early as 16 min after ingestion. For the 10 mg dose level of vardenafil, t max was reported slightly longer (B0.9 h) than for the 20 and 40 mg dose levels (B0.7 h). [16] [17] [18] Tadalafil has a t max of approximately 2 h and an onset time of 30-120 min post-dose, but onset times as early as 16 min after dosing have also been described. 19, 20 Reported C max values after therapeutic doses of sildenafil, vardenafil, and tadalafil ranged between 127 and 560 mg/l (25-100 mg), 16 9.05 mg/l and 20.9 mg/l (10-20 mg), [16] [17] [18] and 378 mg/l (20 mg), 16, 21 respectively. Sildenafil and vardenafil have only a limited oral bioavailability, predominantly because of extensive presystemic metabolism in the gut wall and hepatic first-pass metabolism via CYP3A4 and/or CYP3A5. The mean absolute oral bioavailability is approximately 38-41% for sildenafil and 15% for vardenafil. 22, 15, 23, 24 Vardenafil's lower and variable oral bioavailability compared to sildenafil seems to be a major factor in its larger between-and withinsubject variability in oral clearance and systemic exposure compared to sildenafil and tadalafil. Absolute bioavailability of tadalafil following oral dosing has not been reported, but at least 36% of the dose is absorbed from an oral solution. 25 Administration of a high fat meal had no significant effect on the rate and extent of absorption of tadalafil, but decreased the rate of absorption for sildenafil and vardenafil. When sildenafil was taken with a high-fat meal, t max was delayed by approximately 1 h, C max reduced by 29%, and AUC reduced by 11%. 26 When 20 mg oral vardenafil was administered immediately after consumption of a high-fat breakfast, the mean C max was 18% lower and the median t max was delayed by 1 h, but there was no change in AUC, and the relative bioavailability compared to administration after an overnight fast was 101%. The absorption and PD properties of tadalafil are not affected by food, and thus the drug can be administered without regard for food consumption. 27 Although this has been interpreted as an advantage for tadalafil by eliminating the need to coordinate the timing of meals around sexual activity, it remains so far unclear whether the foodinduced increase in t max and decrease in C max for sildenafil and vardenafil have clinical relevance.
Distribution of PDE5 inhibitors
All three PDE5 inhibitors have a high volume of distribution, which substantially exceeds total volume of body water (approximately 42 l), indicating distribution into tissues and possibly binding to extravascular proteins. After intravenous administration, the mean steady-state volume of distribution (V ss ) is 105 l for sildenafil and 208 l for vardenafil. 26, 28 Tadalafil has an apparent volume of distribution (V/F) of 60-70 l. 29 A negligible amount of the administered PDE5 inhibitor dose appeared in the semen of study subjects for all three compounds, suggesting a low likelihood of any effects in the partners of patients taking them.
All three PDE5 inhibitors are similarly highly bound to plasma proteins. Sildenafil and its active Pharmacokinetics and pharmacodynamics in PD-5 inhibitor therapy B Meibohm et al 30 Vardenafil is 93-95% bound, approximately 80% to albumin and 11% to a 1 -acid glycoprotein. 31 Plasma protein binding for tadalafil was reported as 94%, with a 1 -acid glycoprotein and albumin as principal binding proteins. 25 
Metabolism of PDE5 inhibitors
The CYP3A system is the chief metabolic pathway for sildenafil, vardenafil, and tadalafil. In addition, CYP2C9, CYP2C19, and CYP2D6 also contribute to the metabolism of sildenafil, and CYP2C9 to the metabolism of vardenafil ( Table 1 ). The metabolic pathways for sildenafil and vardenafil are quite complex, with 16 and 14 different metabolites identified, respectively. Tadalafil is primarily metabolized by CYP3A4 to a catechol metabolite, which further undergoes extensive methylation and glucuronidation to form methylcatechol and methylcatechol glucuronide metabolites. 25 Both sildenafil and vardenafil have active metabolites that reach plasma concentrations high enough to contribute to the overall efficacy and safety profile of these drugs. The major circulating metabolite for sildenafil is N-desmethyl sildenafil (UK-103 320) that has been shown to possess 50% of the parent drug's potency for inhibiting PDE5 and accounts for approximately 20% of the pharmacological effects of sildenafil. 30 The three major circulating metabolites of vardenafil also possess pharmacological activity. The major circulating metabolite, M1, has 28% of vardenafil's potency for PDE5 inhibition, whereas the other two metabolites possess 5.6 and 4.9%, respectively. Based on a systemic exposure of 26% of the parent compound, M1's contribution to the overall vardenafil activity is 7%. The main circulating metabolite of tadalafil in plasma is methylcatechol glucuronide, which has more than 10 000-fold less affinity for PDE5 than the parent drug, and is thus expected to be clinically inactive at observed metabolite concentrations. 29 
Elimination of PDE5 inhibitors
The major route of elimination for all PDE5 inhibitors is hepatic metabolism, with renal excretion of unchanged drug accounting for 1% or less of the elimination pathways. Sildenafil is primarily excreted as metabolites into the feces (73-88%) and to lesser extent into the urine (6-15%), with no unchanged sildenafil being detected in either urine or feces after oral administration. Similarly, vardenafil is extensively metabolized after oral administration and predominantly excreted as metabolites in the feces (91-95%) and to a small extent in the urine (2-6%). 23 Only 1% of the administered dose of vardenafil is excreted into urine in unchanged form. 31 Tadalafil is also excreted primarily as inactive metabolites after oral administration, mainly in the feces (61%) and to a lesser extent in the urine (36%). 29 Sildenafil has a systemic clearance of 41 l/h determined after i.v. administration in healthy subjects. 26 The population estimate for oral clearance (CL/F) of sildenafil in patients with ED was 58.5 l/h. 32 The total body clearance of vardenafil after i.v. administration is with 56 l/h similar to that of sildenafil. 18, 28 Sildenafil and vardenafil can be classified as non-restrictively cleared drugs with intermediate to high hepatic extraction ratio based on their relatively high systemic clearance after i.v. administration. 15, 33 Consistent with this classification, sildenafil and vardenafil have both a relatively low oral bioavailability owing to extensive first-pass metabolism. Contrary to that, tadalafil has a mean oral clearance of 2.5 l/h in healthy subjects, and can be classified as a drug with low hepatic extraction ratio. 15 The relatively comparable distribution volumes together with the substantial differences in systemic clearance among the PDE5 inhibitors result in distinct differences of their elimination half-lives, 3-5 h for sildenafil and 4-5 h for vardenafil compared to 17.5 h for tadalafil. The longer half-life of tadalafil results in a broad window of clinical responsiveness compared to sildenafil and vardenafil. This longer duration of action requires fewer time constraints for the effectiveness of tadalafil and has been interpreted as advantageous by providing the option for more spontaneous sexual activity. Tadalafil, however, has been detected in plasma even 5 days after oral administration owing to its long halflife. This suggests the possibility of drug accumulation if taken regularly and in short intervals, which may result in an increased risk of side effects with the excessive use of this PDE5 inhibitor. 15 Exposure-response relationship of PDE5 inhibitors According to US and European labeling information, the recommended starting dose for sildenafil in most patients is 50 mg taken, as needed, approximately 1 h before sexual activity. 34, 35 This dose of sildenafil can be titrated, depending on efficacy and tolerability, up to 100 mg or down to 25 mg. For most patients, the recommended starting dose for vardenafil is 10 mg, which according to US labeling information should be taken approximately 60 min before sexual activity and according to European Union (EU) labeling information 25-60 min before sexual activity. 22, 31 The vardenafil dose may be increased to a maximum of 20 mg or decreased to 5 mg based on efficacy and tolerability. The recommended starting dose of tadalafil varies across global Pharmacokinetics and pharmacodynamics in PD-5 inhibitor therapy B Meibohm et al markets. In the US and Europe, the recommended dose for tadalafil is 10 mg before sexual activity, with a maximum recommended dosing frequency of once daily. 21, 25 Doses can be adjusted based on efficacy and tolerability to a higher (20 mg) or lower (5 mg) daily dose.
No clear concentration-effect relationships have been established for any of the three PDE5 inhibitors. Limited exposure-response assessments for sildenafil revealed that neither the AUC of sildenafil nor of its major active metabolite nor a combination of both were better predictors of outcome than dose. In a dose-response study of sildenafil, it was seen that increasing doses of sildenafil were associated with improved erectile function, as measured by questionnaires about achieving and maintaining erections. 36 However, there was no obvious correlation between plasma concentrations of sildenafil and its metabolites and time to onset of erections or duration of rigidity. Using an E max model, the average ED 50 was estimated as 36-41 mg based on various questionnaire-derived effectiveness scores. Diabetic patients were suggested to be less responsive with higher ED 50 estimates of 182 mg. 34 The incidence of adverse events was much larger with the 200 mg dose of sildenafil than with lower doses. At this dose level, AUC values in excess of 2600 mg h/l and C max values in excess of 500 mg/l were associated with a 40% incidence of abnormal vision episodes, 15% incidence of gastrointestinal events, and 25% incidence of vascular events. 34 For vardenafil, exposure-response assessments have so far been limited to two relatively small Phase II studies comparing the effect of oral vardenafil doses of 10 vs 20 and 20 vs 40 mg on penile rigidity and tumescence. 17, 18, 31 Although all doses showed significant efficacy compared to placebo, there was no evidence of a dose-dependent improvement in efficacy beyond the 10 mg dose.
Tadalafil's efficacy in ED is characterized by a distinct nonlinear, saturable dose-response relationship that was characterized using an E max model. 37 ED severity was identified to account for a large portion of the between-patient variability in the dose-response relationship, with greater improvement in erectile function in more severely affected individuals. 27, 37 The absolute performance at any dose level, however, was the highest in the least severely affected individuals. The tadalafil doses required to achieve half-maximal improvement (ED 50 ) as quantified by the International Index of Erectile Function questionnaire were 4.7, 7.1, and 10.1 mg for patients with mild, moderate, and severe ED, respectively. 15, 37 PDE selectivity and adverse events The pharmacodynamics of PDE5 inhibitors are determined by their potency and selectivity towards PDE inhibition. Sildenafil, vardenafil, and tadalafil all differ in their potency and selectivity for the 11 known PDE families, which gives rise to differences in their activity and side effect profiles.
All three drugs are potent inhibitors of PDE5. The drug concentration producing half of the maximum inhibition of PDE5 activity, IC 50 , was reported as 3.5-8.5 nM for sildenafil, 0.1-0.7 nM for vardenafil, and 0.94-6.4 nM for tadalafil. 25, 31, 34, 38, 39 Thus, vardenafil is the PDE5 inhibitor with the highest potency.
More differentiating for the pharmacodynamics of PDE5 inhibitors, however, is selectivity rather than potency. Selectivity of PDE5 inhibition is expressed as ratio between the IC 50 for a given PDE and the IC 50 for inhibition of PDE5. From the selectivity ratios listed in Table 2 , it becomes obvious that potential side effects may arise from inhibition of PDE1, PDE6, or PDE11 during the pharmacotherapy with PDE5 inhibitors. [38] [39] [40] For PDE1, selectivity ratios for sildenafil and vardenafil are clearly below those of tadalafil, but have a relative wide margin of 41-136-fold selectivity. Inhibition of PDE1 may be clinically relevant as PDE1 is expressed in the brain, in myocardial cells, and in vascular smooth muscle cells. Inhibition of PDE1 subtypes may induce vasodilation, tachycardia, and flushing. 38 Lately, a lot of attention has been directed towards the nonselectivity of PDE5 inhibitors towards PDE6. PDE6 is expressed only in the retina and is relevant for visual transduction. Inhibition of PDE5 has been shown to disturb vision. The FDA recently reported a potential link between a small number of cases of vision loss owing to non-arteritic anterior ischemic optic neuropathy and the use of sildenafil, vardenafil, and tadalafil. Tadalafil is clearly more selective than either vardenafil or sildenafil towards PDE5 relative to PDE6 inhibition (Table 2) . This difference in the selectivity ratio of tadalafil compared to sildenafil or vardenafil may account for the Selectivity ratios expressing the fold differences in inhibitory activity for a specific PDE compared to PDE5. [38] [39] [40] Abbreviation: PDE, phosphodiesterase.
Pharmacokinetics and pharmacodynamics in PD-5 inhibitor therapy B Meibohm et al 261 lower frequency of visual side effects with tadalafil (o0.1%) compared to sildenafil (e.g., color tinge to vision (chromatopsia), increased sensitivity to light or blurred vision in p3% of patients), or vardenafil (e.g. blurred vision, chromatopsia in o1% of patients) at therapeutic doses. 41 The physiological relevance of PDE11 is yet unknown, but PDE11 is found, among other places, in skeletal muscle tissue. Tadalafil is the PDE5 inhibitor with the lowest selectivity ratio with regard to PDE11. Back pain and myalgia are more common with tadalafil than with other PDE5 inhibitors, possibly owing to its effects on PDE11. Myalgia and back pain, however, have also been reported during treatment with sildenafil and vardenafil, although the effects occurred less frequently. 38, 41 Overall, treatment of ED with PDE5 inhibitors is generally well tolerated, and the side effect profiles of all three drugs are remarkably similar, with all having some propensity to produce headache, flushing, rhinitis, dyspepsia, and myalgia. All of these are likely to be related either directly or indirectly to the primary action of the drugs as PDE5 inhibitors. 16 
Drug interactions of PDE5 inhibitors
As metabolism via CYP3A is the major elimination pathway for all three PDE5 inhibitors, all inducers and inhibitors of CYP3A activity have the potential to interfere with the systemic exposure and elimination of sildenafil, vardenafil, and tadalafil. A listing of PK and PD interactions potentially requiring dosing adjustments is provided in Table 3 .
For inducers of CYP3A activity, the interaction potential has clinically been verified only for rifampin and tadalafil. Nevertheless, it is expected that pretreatment with inducers of CYP3A4 will result in a decrease of systemic exposure for the PDE5 inhibitors. For strong inhibitors of CYP3A-mediated metabolism, systemic exposure for these PDE5 inhibitors was observed to be increased after ritonavir, indinavir, saquinavir, erythromycin, and ketoconazole. Grapefruit juice as a selective inhibitor of CYP3A-mediated gut metabolism also increased the systemic exposure to sildenafil and vardenafil, underlining the substantial contribution of presystemic metabolism to the overall elimination of these compounds. Similarly, systemic exposure for both drugs was increased during concomitant therapy with the nonspecific CYP inhibitor cimetidine. Notably, ritonavir as an inhibitor of CYP3A as well as CYP2C-mediated metabolism had an unusually strong effect on vardenafil, increasing systemic exposure on average 49-fold with individual values as high as 300-fold, most likely as a consequence of simultaneous inhibition of the CYP3A4 and CYP2C9-mediated major elimination routes of vardenafil and the intestinal export transporter P-glycoprotein. The effect of ritonavir on sildenafil was much less pronounced (11-fold), as other compensatory elimination pathways besides CYP3A4 and CYP2C9 were still available. 15 For the CYP3A, but not CYP2C substrate tadalafil, the increase in systemic exposure was only 2.6-fold under concomitant ritonavir therapy. Nevertheless, in contrast to EU prescribing information, US labeling only recommends 50% dose reduction, but no contraindication for concomitant use of vardenafil and ritonavir. 25, 43 Tadalafil's rate of absorption was decreased by up to 30% when coadministered with antacids. No effect was observed for sildenafil or vardenafil when concomitantly administered with antacids. 31, 35 Administration of sildenafil, vardenafil, and tadalafil is contraindicated with nitrates, as PDE5 Pharmacokinetics and pharmacodynamics in PD-5 inhibitor therapy B Meibohm et al inhibitors are known to potentiate the hypotensive effect of nitrates. In addition, sildenafil (100 mg) has also been shown to potentiate the hypotensive effect of amlodipine (5 or 10 mg) and doxazosin (4 mg). 44 Similarly, vardenafil (10 or 20 mg) when concomitantly administered with a-blockers (such as terazosin and tamsulosin) and with nifedipine to healthy volunteers resulted in some subjects experiencing hypotension. Any a-adrenergic antagonist other than 0.4 mg once-daily tamsulosin is contraindicated, as tadalafil (20 mg) significantly enhanced the blood-pressure-lowering effect of doxazosin. There is also evidence of a PD interaction between 20 mg tadalafil and chronically administered angiotensin AT 1 receptor antagonists in hypertensive subjects. A more detailed description of all the studied PK and PD interactions with sildenafil, vardenafil, and tadalafil has been described elsewhere.
15

PDE5 inhibitors in special populations
The well-described reduction in metabolic activity of CYP3A and CYP2C with age is reflected by an increase in systemic exposure to all three PDE5 inhibitors. 45 In men aged X65 years, the AUC of sildenafil was about twice as high and mean C max values about 60-70% higher than in younger men. 34, 35 For vardenafil, the AUC and C max are increased by 52 and 34%, respectively, in elderly men. Hence, lower starting doses are recommended for older men, that is, 25 mg for sildenafil and 5 mg for vardenafil. 22, 31 No such adjustments are necessary for elderly men taking tadalafil. 25, 43 Severe renal impairment resulted in an increase in systemic exposure for all three drugs, but warranted dose reductions for sildenafil and tadalafil in the affected patient population. For sildenafil, administration of an oral dose of 50 mg to subjects with severe renal impairment resulted in doubling of AUC and C max of sildenafil and its active metabolite compared to subjects without renal impairment. 23 For vardenafil, patients with moderate (creatinine clearance 30-50 ml/min) and severe renal impairment (creatinine clearance o30 ml/min) had a slightly higher vardenafil exposure as compared to healthy subjects, with increases of 31 and 21%, respectively. 17 For tadalafil, a single dose of 5-10 mg tadalafil resulted in doubling of the AUC in subjects with mild or moderate renal impairment. In subjects with end-stage renal disease on hemodialysis, a twofold increase in C max and 3.7-4.1-fold increase in AUC was seen following administration of a 10 or 20 mg tadalalafil dose, respectively. 41, 43 As renal elimination contributes only 1% or less to the systemic clearance for all of these drugs, the increase in systemic exposure is most likely the consequence of an indirect inhibition of hepatic function secondary to renal impairment, probably through accumulation of endogenous substances that inhibit hepatic drug-metabolizing enzymes, and/or via hemodynamic changes affecting liver blood flow. 15 Mild and moderate hepatic impairment increased C max and AUC for sildenafil and vardenafil, but had no significant effect on tadalafil pharmacokinetics. In subjects with hepatic dysfunction (Child-Pugh A and B), sildenafil oral clearance was reduced by 46%, resulting in an 84% increase in AUC, a 47% increase in C max , and a 34% prolongation of t 1/2 . 34, 35 Whereas subjects with mild hepatic impairment (Child-Pugh A) experienced a vardenafil C max and AUC increase by 22 and 17%, respectively, compared to subjects with normal hepatic function after a 10 mg vardenafil dose, the increase in subjects with moderate hepatic impairment (Child-Pugh B) was 130 and 160%, respectively. 22, 31 US labeling information for vardenafil recommends a lower starting dose of the drug (5 mg) in patients with moderate hepatic impairment, and the maximum dose should not exceed 10 mg. 31 In subjects with mild and moderate hepatic insufficiency, administration of a 10 mg dose of tadalafil resulted in a systemic exposure comparable to healthy subjects, suggesting that this degree of hepatic impairment does not have any significant impact on the pharmacokinetics of tadalafil. 25, 43 So far, severe hepatic insufficiency has not been studied for any of the PDE5 inhibitors. Table 3 contains a compilation of special populations for which dosage adjustments are warranted.
Conclusions
Differences in the pharmacokinetics and pharmacodynamics of currently marketed PDE5 inhibitors result in substance-specific properties relevant to their risk-benefit profile and clinical use as well as differential requirements for dosage adjustments in drug-drug interactions and special populations. Sildenafil and vardenafil are very similar in terms of their chemical structure, whereas tadalafil has a markedly different structure. 15 These chemical similarities and differences are also reflected in similarities and dissimilarities of the clinical pharmacokinetics and pharmacodynamics among these compounds. Appreciation of these substance-specific clinical pharmacology profiles will allow for a rationale dosage and compound selection based on the individual needs of the patient.
